Pollinex Quattro Tree: allergy vaccine.
An overview of short-term specific immunotherapy (ST-SIT) highlighting Pollinex Quattro (PQ) Tree is presented. The product development of this novel allergy vaccine using modifying agent glutaraldehyde, adjuvant monophosphoryl lipid and L-tyrosine have heralded a superior ST-SIT. Since 1999 when PQ was founded in Germany, various research trials assessing both the standardization and clinical studies have been done. A review of these studies demonstrates the efficacy and safety of PQ Tree in both pediatric and adult trials. The uniqueness of this product allows a shorter course of four pre-seasonal injections to provide control of allergy symptomatology in seasonal rhinitis patients. The PQ Tree product studies show a similar efficacy and safety profile to the grass formulation trial.
Gawchik
Sandra M
SM
Asthma & Allergy Research Associates, President's Drive, Upland, PA 19013, USA. smgawchik@aol.com
Saccar
Consuelo L
CL
D002986:Clinical Trials as Topic; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology; D014197:Trees / Q000737:chemistry / Q000276:immunology; D014612:Vaccines / Q000627:therapeutic use*
C516537:Pollinex Quattro; D014612:Vaccines